11 stories mentioning SHA:603087Updated 1d ago
Every FINWIRES story that references SHA:603087, newest first.
Gan & Lee Pharmaceuticals (SHA:603087) obtained the approval of China's medical products regulator to conduct clinical trials for its GLR1075 injection.The drug is intended to treat hypoalbuminemia in cirrhotic ascites, according to a weekend filing with the Shanghai bourse.Shares of the pharmaceutical company rose 3% in recent trade.
Gan & Lee Pharmaceuticals (SHA:603087) said the first subject has been dosed in the first phase clinical trial of GZC8072 tablets.The drug is an oral once-weekly peptide formulation for obesity and type two diabetes, according to a Tuesday filing with the Shanghai bourse.Shares of the pharmaceutical company rose 1% in recent trade.
Gan & Lee Pharmaceuticals (SHA:603087) said its subsidiary received China's regulatory approval to start clinical trials for GZC8072 tablets.The drug is a novel once-weekly oral GLP-1 therapy for type two diabetes, according to a Friday filing with the Shanghai bourse.Shares of the pharmaceutical company fell 1% in recent trade.
Gan & Lee Pharmaceuticals' (SHA:603087) net profit attributable to shareholders in the first half rose 1% to 609.8 million yuan from 603.7 million yuan a year earlier, according to a Shanghai bourse filing on Wednesday.Earnings per share grew year on year to 1.03 yuan from 1.02 yuan.Operating revenue increased 7.6% to 2.22 billion yuan from 2.07 billion yuan in the previous year.The Chinese pharmaceutical company's shares closed 4% higher.
Gan & Lee Pharmaceuticals' (SHA:603087) Shandong subsidiary received clinical trial approval from China's National Medical Products Administration for its investigational GZC8072 drug for weight control, according to a Tuesday filing with the Shanghai bourse.The tablets use the company's peptide technology platforms for a once-weekly regimen, the diabetes drug maker said.
Gan & Lee Pharmaceuticals (SHA:603087) granted Italian drug manufacturer Menarini licensing rights for the Chinese company's bofanglutide drug for type 2 diabetes and obesity, according to a Tuesday filing with the Shanghai Stock Exchange.The license deal will allow Menarini to develop and commercialize the drug across 39 European countries and regions, including the 27 members of the EU, as well as the UK, Switzerland, Norway, Iceland, Liechtenstein, and the Balkans.Menarini will pay a non-refundable, initial payment of 62 million euros to Gan & Lee, as well as research, market launch, and sales milestone payments of up to 664 million euros, the Chinese diabetes drug company said.Shares surged 10% during afternoon trading on Tuesday.
Gan & Lee Pharmaceuticals (SHA:603087) received clinical trial approval from China's drug regulator for GLR2038 tablets to treat advanced breast cancer.The drug, developed on the company's proprietary PROTAC platform, will proceed to monotherapy trials, according to a weekend filing with the Shanghai bourse.Shares of the pharmaceutical company rose 6% Monday.
Honduran authorities approved Gan & Lee Pharmaceuticals' (SHA:603087) insulin glargine injection for diabetes, according to a Monday filing with the Shanghai bourse.The drug is said to have a hypoglycemic effect lasting 24 hours, the company said in its filing.
The European Commission granted Gan & Lee Pharmaceuticals (SHA:603087) marketing authorization for insulin aspart injection Dazparda, according to a Shanghai bourse filing on Thursday.The Chinese pharmaceutical company's unit, Gan & Lee Pharmaceuticals Europe, is the authorized marketer of the product in Europe.The company's shares rose 1% at the close.
Gan & Lee Pharmaceuticals (SHA:603087) received approval from China's National Medical Products Administration for the clinical trials of GLR1062 injection, according to a Shanghai bourse filing on Thursday.The drug will be tested for the treatment of neovascular (wet) age-related macular degeneration in adults.
Gan & Lee Pharmaceuticals' (SHA:603087) subsidiary, Gan & Lee Pharmaceuticals Shandong, dosed the first subject for the phase III clinical trial of GZR33 injection, according to a Shanghai bourse filing on Wednesday.The drug is being tested as a treatment for type 2 diabetes.The pharmaceutical company's shares rose less than 3% during the afternoon trade.
